Business Wire

MERCANS

11.12.2023 12:01:37 CET | Business Wire | Press release

Share
Mercans Achieves Leadership Status in Global Managed Payroll Services (Multi-Country) - ISG Provider Lens™ 2023

ISG, an independent research firm, has recognized Mercans as a Leader in its exclusive Global Managed Payroll Services (Multi-Country) ISG Provider Lens™ 2023 report. Among 36 Payroll Solutions and Services vendors assessed comprehensively, Mercans emerged as a clear industry leader. This prestigious acknowledgment by a leading analyst firm solidifies Mercans’ position as a technology leader in the payroll industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211410383/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mercans Achieves Leadership Status in Global Managed Payroll Services - ISG Provider Lens™ 2023 (Photo: AETOSWire)

ISG praised Mercans for its Digital Transformation in Streamlined Payroll. Mercans’ single platform gross-to-net payroll engine is revolutionary and has disrupted the global payroll industry. Its G2N Nova is the only stateless global payroll application that enables generating gross-to-net payroll calculations across 100+ countries in seconds and without storing any employee data. This disruptive and innovative approach to global payroll has become the pathway for multinationals to fully digitalize their global payroll operations. In addition to being the only global gross-to-net payroll application, G2N Nova delivers completely autonomous and touchless payroll experience, drastically reducing payroll processing times and costs.

Mercans’ proprietary payroll technology has changed the traditional aggregation and manual processes based global payroll model by eliminating the need for in-country subcontractors and third-party software solutions. Mercans’ payroll platform can be seamlessly integrated with any HR software and allows electronic generation and submission of statutory reports across the globe. G2N Nova cutting-edge horizontal architecture makes it possible to consolidate payroll processing and reporting on a single software that powers SaaS and managed payroll services across thousands of companies and more than 100 countries.

Mercans CEO of Payroll & SaaS, Vishwanathan Arunachalam (Vish), emphasized, “This recognition underscores our comprehensive product and service offerings, robust market presence, and enduring competitive position. We are committed to innovative practices and competitive stability.”

Strengths commended by ISG for Mercans:

  • Streamlined, Efficient Processing
  • Tailored Service Packages
  • Technological Prowess
  • Global Expertise

Rachel Anderson, Lead Analyst at ISG, commends Mercans, stating, “Mercans is a global leader in payroll technology and services. Its proprietary HR Blizz global payroll infrastructure, coupled with native calculation engines, serves the requirements of 160 countries with remarkable finesse.”

This distinction showcases Mercans' dedication to innovation and excellence in Global Payroll Services, setting a high standard for the industry's future.

Read the full ISG Provider Lens™ 2023 report here.

About Mercans

Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll platform HR Blizz enables SMBs & Enterprise businesses to manage payrolls across 160 countries. With 20 years of global payroll expertise, Mercans delivers the full spectrum of HR services through a single, secure global platform.

Visit www.mercans.com

LinkedIn

Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231211410383/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye